SOHM (SHMN) 주식 개요는 미국에서 제네릭 및 자체 상표 의약품을 개발, 제조, 마케팅 및 유통하는 회사입니다. 자세히 보기SHMN 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6위험 분석높은 수준의 비현금 수입지난 1년 동안 주주가 크게 희석되었습니다.의미 있는 시가총액이 없습니다($3M)지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.+ 위험 1건 추가모든 위험 점검 보기SHMN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.001123.6% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-1m1m2016201920222025202620282031Revenue US$1.3mEarnings US$190.9kAdvancedSet Fair ValueView all narrativesSOHM, Inc. 경쟁사Adial PharmaceuticalsSymbol: NasdaqCM:ADILMarket cap: US$3.0mSonoma PharmaceuticalsSymbol: NasdaqCM:SNOAMarket cap: US$3.8mHepion PharmaceuticalsSymbol: OTCPK:HEPAMarket cap: US$2.6mSciSparcSymbol: NasdaqCM:SPRCMarket cap: US$2.4m가격 이력 및 성과SOHM 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$0.001152주 최고가US$0.002152주 최저가US$0.0007베타01개월 변동0%3개월 변동-8.33%1년 변동37.50%3년 변동57.14%5년 변동-78.43%IPO 이후 변동-99.90%최근 뉴스 및 업데이트공시 • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.공시 • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.공시 • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.공시 • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.공시 • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.공시 • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.더 많은 업데이트 보기Recent updates공시 • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.공시 • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.공시 • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.공시 • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.공시 • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.공시 • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.주주 수익률SHMNUS PharmaceuticalsUS 시장7D8.4%5.4%1.2%1Y37.5%44.3%28.7%전체 주주 수익률 보기수익률 대 산업: SHMN은 지난 1년 동안 44.3%의 수익을 기록한 US Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: SHMN은 지난 1년 동안 28.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is SHMN's price volatile compared to industry and market?SHMN volatilitySHMN Average Weekly Movement19.0%Pharmaceuticals Industry Average Movement9.9%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%안정적인 주가: SHMN의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: SHMN의 주간 변동성은 지난 1년간 26%에서 19%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트2005n/aBaron Nightwww.sohm.com는 미국에서 제네릭 및 자체 상표 의약품을 개발, 제조, 마케팅 및 유통하는 회사입니다. 이 회사는 진통제, 항생제, 감기약, 항염증제뿐만 아니라 일반의약품, 코스메슈티컬, 건강기능식품을 제공합니다. 또한 제품 수출도 하고 있습니다.더 보기SOHM, Inc. 기초 지표 요약SOHM의 순이익과 매출은 시가총액과 어떻게 비교됩니까?SHMN 기초 통계시가총액US$3.19m순이익 (TTM)-US$1.13m매출 (TTM)US$1.30m0.0x주가매출비율(P/S)0.0x주가수익비율(P/E)SHMN는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표SHMN 손익계산서 (TTM)매출US$1.30m매출원가US$962.58k총이익US$333.87k기타 비용US$1.47m순이익-US$1.13m최근 보고된 실적Dec 31, 2012다음 실적 발표일해당 없음주당순이익(EPS)0총이익률0.00%순이익률0.00%부채/자본 비율0.0%SHMN의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 10:30종가2026/05/22 00:00수익2012/12/31연간 수익2012/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SOHM, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.
공시 • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.
공시 • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.
공시 • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.
공시 • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.
공시 • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.
공시 • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.
공시 • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.
공시 • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.
공시 • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.
공시 • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.
공시 • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.
